Incidence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum isolated in Brescia, Italy, over 7 years

Journal of Infection and Chemotherapy

Volumn 19, Issue 4, 2013, Pages 621-627

  De Francesco, Maria Antonia ^a   Caracciolo, Sonia ^a   Bonfanti, Carlo ^a   Manca, Nino ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Antibiotic; Mycoplasma hominis; Resistance; Susceptibility; Ureaplasma urealyticum

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; JOSAMYCIN; OFLOXACIN; PRISTINAMYCIN; TETRACYCLINE;

ADULT; AGE DISTRIBUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CROSS RESISTANCE; DRUG CHOICE; DRUG EFFICACY; FEMALE; HUMAN; INCIDENCE; ITALY; MIXED INFECTION; MYCOPLASMA HOMINIS; MYCOPLASMOSIS; NONHUMAN; PREVALENCE; UREAPLASMA UREALYTICUM; UROGENITAL TRACT INFECTION;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INCIDENCE; ITALY; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA HOMINIS; MYCOPLASMA INFECTIONS; RETROSPECTIVE STUDIES; UREAPLASMA INFECTIONS; UREAPLASMA UREALYTICUM;

EID: 84882284713     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0527-z     Document Type: Article

References (26)

1. Clegg A, Passey M, Yoannes M, Michael A. High rates of genital mycoplasma infection in the highlands of Papua New Guinea determined both by culture and by a commercial detection kit. J Clin Microbiol. 1997;35:197-200.
2. Kechagia N, Bersimis S, Chatzipanagiaotou S. Incidence and antimicrobial susceptibilities of genital mycoplasmas in outpatient women with clinical vaginitis in Athens, Greece. J Antimicrob Chemother. 2008;62:122-5.
3. Taylor-Robinson D. The role of mycoplasmas in pregnancy outcome. Best Pract Res Clin Obstet Gynaecol. 2007;21:425-38.
4. Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev. 2005;18:757-89.
5. Waites KB, Schelonka RL, Xiao L, Grigsby PL, Novy MJ. Congenital and opportunistic infections: Ureaplasma species and Mycoplasma hominis. Semin Fetal Neonatal Med. 2009;14:190-9.
6. Bilhari A. Screening of sexually transmitted diseases (Mycoplasma hominis, Ureaplasma urealyticum and Chlamydia trachomatis) in young women. Orv Hetil. 1997;138:799-803.
7. Zdrodowska-Stefanow B, Klosowska WM, Ostaszewska-Puchalska I, Buthak-Koziol V, Kotowicz B. Ureaplasma urealyticum and Mycoplasma hominis infection in women with urogenital diseases. Adv Med Sci. 2006;51:250-3.
8. Bébéar CM, Renaudin H, Charron A, Clerc M, Pereyre S, Bébéar C. DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones. Antimicrob Agents Chemother. 2003;47:3323-5.
9. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother. 2001;45:2604-8.
10. Taylor-Robinson D, Bébéar C. Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections. J Antimicrob Chemother. 1997;40:622-30.
11. Waites KB, Crabb DM, Bing X, Duffy LB. In vitro susceptibilities to and bacterial activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother. 2003;47:161-5.
12. McCormark WM. Susceptibility of mycoplasmas to antimicrobial agents: clinical implications. Clin Infect Dis. 1993;17(suppl S1):200-10.
13. Dégrange S, Renaudin H, Charron A, Bébéar C, Bébéar CM. Tetracycline resistance in Ureaplasma spp. and Mycoplasma hominis: prevalence in Bordeaux, France, from 1999 to 2002 and description of two tet(M)-positive isolates of M. hominis susceptible to tetracycline. Antimicrob Agents Chemother. 2008;52:742-4.
14. Furneri PM, Rappazzo G, Musumarra MP, Di Pietro P, Catanis JS, Roccasalve LS. Two new point mutations at A2062 associated with resistance to 16-membered macrolide antibiotics in mutant strains of Mycoplasma hominis. Antimicrob Agents Chemother. 2001;45:2958-60.
15. Pereyre S, Renaudin H, Charron A, Bébéar C, Bébéar CM. Emergence of a 23S rRNA mutation in Mycoplasma hominis associated with a loss of the intrinsic resistance to erythromycin and azithromycin. J Antimicrob Chemother. 2006;57:753-6.
16. Pereyre S, Métifiot M, Cazanave C, Renaudin H, Charron A, Bébéar C, et al. Characterisation of in vitro-selected mutants of Ureaplasma parvum resistant to macrolides and related antibiotics. Int J Antimicrob Agents. 2007;29:207-11.
17. McCormark WM, Rein MF. Urethritis. In: Mandell GL, Bennet JE, Dolin R, editors. Principle and practice of infectious diseases. New York: Churchill Livingstone; 2000. p. 1208-17.
18. Domingues D, Tavora Tavira L, Duarte A, Sanca A, Prieto E, Exposto F. Genital mycoplasmas in women attending a family planning clinic in Guiné-Bissau and their susceptibility to antimicrobial agents. Acta Trop. 2003;86:19-24.
19. Kataoka S, Yamada T, Chou K, Nishida R, Morikawa M, Minami M, et al. Association between preterm birth and vaginal colonization by mycoplasmas in early pregnancy. J Clin Microbiol. 2006;444:51-5.
20. De Francesco MA, Negrini R, Pinsi G, Peroni L, Manca N. Detection of Ureaplasma biovars and polymerase chain reaction-based subtyping of Ureaplasma parvum in women with or without symptoms of genital infections. Eur J Clin Microbiol Infect Dis. 2009;28:641-6.
21. Taylor-Robinson D, Furr PM. Update on sexually transmitted mycoplasmas. Lancet. 1998;351:12-5.
22. Chaim W, Mazor M, Leiberman JR. The relationship between bacterial vaginosis and preterm birth. Arch Gynecol Obstet. 1997;259:622-30.
23. Ngan CCL, Lim T, Choo C-M, Toh GL-X, Lim Y-S. Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method. Diagn Microbiol Infect Dis. 2004;48:207-10.
24. Samra Z, Rosenberg S, Soffer Y. In vitro susceptibility of Mycoplasma hominis clinical isolates to tetracyclines, quinolones and macrolides. Diagn Microbiol Infect Dis. 2002;44:359-61.
25. Krausse R, Schubert S. In vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma spp. isolated in Germany over 20 years. Clin Microbiol Infect. 2010;16:1649-55.
26. Duffy KB, Crabb D, Searcey K, Kampf MC. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. J Antimicrob Chemother. 2000;45(suppl):S29-33.